Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Organon (OGN) to $9 from $10 and keeps an Equal Weight rating on the shares. The company, which announced that it had identified and ceased the improper sales practices that resulted in recent personnel changes and concluded that improper practices were limited to Nexplanon, lowered revenue guidance to $6.2B-$6.25B from $6.275B-$6.375B, predominantly driven by U.S. policy headwinds for Nexplanon and challenges in the respiratory business, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon & Co. Reports Modest Q3 Revenue Growth
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- Morning Movers: Monday.com sinks following third quarter results
- Organon cuts FY25 revenue view to $6.2B-$6.25B from $6.28B-$6.38B
- Organon reports Q3 adjusted EPS $1.01, consensus 93c